Comparative effects of quinapril with enalapril in rats with heart failure

Pharmacology

Volumn 71, Issue 3, 2004, Pages 157-161

  Watanabe, Kenichi ^a   Ma, Meilei ^a   Wen, Juan ^a   Tachikawa, Hitoshi ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b   Yamaguchi, Kenichi ^b   Takahashi, Toshihiro ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Enalapril; Heart failure; Quinapril; Transforming growth factor

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MESSENGER RNA; QUINAPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; HEART VENTRICLE FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARDIOMYOPATHY, DILATED; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; FIBROSIS; MALE; MYOCARDIUM; RATS; RATS, INBRED LEW; RNA, MESSENGER; SURVIVAL RATE; TETRAHYDROISOQUINOLINES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 2642560159     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077450     Document Type: Article

References (23)

1. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M: A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;325:303-310.
2. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
3. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH: Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994;90:1410-1422.
4. Litwin SE, Kats SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS: Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 1995;91:2642-2654.
5. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
6. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
7. Masuell M, Brusca G, Pardo A, Pineiro D, Checkerdhernian S, Forcada P: ACE inhibitors in heart failure - Switching from enalapril to perindopril. Curr Med Res Opin 2002;18:296-302.
8. Mizuno Y, Yasue H, Yoshimura M, Fujii H, Yamamoto N, Nakayama M, Harada E, Sakamoto T, Nakamura S, Ito T, Shimasaki Y, Ogawa H, Saito Y, Nakao K: Effects of perindopril on aldosterone production in the failing human heart. Am J Cardiol 2002;89:1197-1200.
9. Ruzicka M, Skarda V, Leenen HHF: Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568-3573.
10. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
11. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
12. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
13. Schelling P, Fisher PH, Ganten D: Angiotensin and cell growth: A link to cardiovascular hypertrophy. J Hypertens 1991;9:3-15.
14. Wen J, Nakazawa M, Watanabe K, Ma M, Wahed M, Hasegawa G, Naito M, Yamamoto T, Fuse K, Kato K, Kodama M, Aizawa Y: Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem 2003;251:77-82.
15. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A: Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-284.
16. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y: Low-dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 2000;130:1489-1495.
17. Watanabe K, Wen J, Narasimman G, Ma M, Inoue M, Saito Y, Wahed M, Nakazawa M, Hasegawa G, Naito M, Tachikawa H, Tanabe N, Kodama M, Aizawa Y, Yamamoto T, Yamaguchi K, Takahashi T: Comparative effects of angiotensin II receptor blockade (candesartan) with ACE inhibitor (quinapril) in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol 2003;41(suppl 1):93-97.
18. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y: Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 2000;36(suppl 2):19-23.
19. Chomczynski P, Sacchi N: Single-step method of mRNA by acid guaniginium thiocyanatephenol-chloroform extraction. Anal Biochem 1987;162:156-159.
20. Watanabe K, Saito Y, Ma M, Wahed M, Abe Y, Hirabayashi K, Narasimman G, Juan W, Suresh P, Ali F, Shirai K, Soga M, Nagai Y, Nakazawa M, Hasegawa G, Naito M, Tachikawa H, Kodama M, Aizawa Y, Yamaguchi K, Takahashi T: Comparative effects of perindopril with enalapril in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol 2003;42(suppl 1):105-109.
21. MacMahon S, Chalmers J: Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J 2003;24:391-393.
22. Lear W, Ruzicka M, Leenen F: ACE inhibitors and cardiac ACE mRNA in volume overloadinduced cardiac hypertrophy. Am J Physiol 1997;273:H641-H646.
23. Hornig B, Arakawa N, Haussmann D, Drexler H: Differential effects of quinapril and enalapril on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;98:2842-2848.